SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...

Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI ...

The new AI-powered Smart Food Logging feature supports greater personalized insights into how meals are impacting glucose levels Users can now take a photo of their food in their Stelo or Dexcom G7 ...

In March 2024, the FDA approved the first over-the-counter continuous glucose monitors (CGMs), marking a quiet but significant shift in how we can track and understand our health. Devices like ...

Blood glucose giant Dexcom has used CES 2024 to announce a new continuous glucose monitor (CGM) designed specifically for Type 2 diabetics who don’t use insulin – Dexcom Stelo. The Stelo still ...

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...

The device is similar to existing prescription CGMs. Users pair the wearable sensor with an application, put it on their arm and receive a continuous stream of glucose data on their smartphone or ...

Tuesday, the FDA approved DexCom Inc’s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...

SAN FRANCISCO, June 23, 2025 /PRNewswire/ -- Stelo, an enterprise software company, has filed suit in Federal District Court for the Central District of California against San Diego-based Dexcom, Inc.

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Dexcom (DXCM – Research Report) and keeping the price target at $80.00. Larry Biegelsen has given his Buy rating due to a ...